Evaxion to present new data at AACR Annual Meeting

Rhea-AI Summary

Evaxion (NASDAQ: EVAX) announced two abstracts accepted for presentation at the AACR Annual Meeting in San Diego, April 17-22, 2026. One poster reports new biomarker and immunogenicity data for the personalized cancer vaccine EVX-01 in advanced melanoma; the other reports use of the AI-Immunology™ platform to identify ERV-derived neoantigens for personalized glioblastoma vaccines. Evaxion will also attend the AACR Oncology Industry Partnering event to seek partnerships and collaborations. Presentations are scheduled on April 22, 2026, at 9:00–12:00 CST (16:00–19:00 CET).

Key Figures

AACR abstracts: 2 abstracts AACR dates: April 17–22, 2026 Poster number EVX-01: #7741 +4 more

7 metrics

AACR abstracts 2 abstracts Accepted for presentation at AACR Annual Meeting 2026

AACR dates April 17–22, 2026 AACR Annual Meeting in San Diego

Poster number EVX-01 #7741 AI-designed personalized neoantigen vaccine EVX-01 poster

Poster number glioblastoma #6975 ERV-derived neoantigens in glioblastoma strategy poster

Session time (CST) 9am–12pm CST Poster presentation window on April 22, 2026

Session time (CET) 16–19 CET Poster presentation window on April 22, 2026

IR phone +45 53 54 82 96 Investor Relations contact number in release

Market Reality Check

Price: $3.83 Vol: Volume 25,841 vs 20-day a...

normal vol

$3.83 Last Close

Volume Volume 25,841 vs 20-day average 32,968 (relative 0.78x), so activity was quieter into this news. normal

Technical Shares at $3.83 are trading below the 200-day MA at $4.05, after a -10.33% 24h move and -68.48% vs 52-week high.

Peers on Argus

EVAX fell 10.33% while close peers showed mixed, modest moves: GOVX +1.2%, IBIO ...

EVAX fell 10.33% while close peers showed mixed, modest moves: GOVX +1.2%, IBIO +2.07%, SYBX +0.75%, PULM -0.47%, LSTA -0.2%. This points to stock-specific pressure rather than a broad biotech move.

Historical Context

5 past events · Latest: Mar 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 05	Full-year 2025 results	Positive	+9.3%	Stronger 2025 finances, MSD deal, EVX-01 data and extended cash runway.
Mar 05	Annual report timing	Neutral	+9.3%	Slight delay in 2025 annual report filing due to technical vendor issues.
Mar 02	Earnings call scheduling	Neutral	+0.3%	Announcement of date and time for full-year 2025 business update.
Jan 13	Platform expansion	Positive	-1.5%	Expansion of AI-Immunology™ into autoimmune with milestones outlined for 2026.
Jan 07	Conference milestones	Positive	+6.7%	Presentation of 2026 milestones and corporate update at Biotech Showcase.

Pattern Detected

Recent history shows positive reactions to major data/financial updates, but occasional divergence where seemingly minor or logistical news still coincided with notable upside or downside.

Recent Company History

Over recent months, Evaxion has focused on its AI-Immunology™ platform, key oncology assets, and financial strengthening. On Jan 7, 2026, it highlighted 2026 milestones and conference visibility, followed by a platform expansion into autoimmune diseases on Jan 13, 2026. March events centered on full-year 2025 results, improved cash into H2 2027, and technical filing issues. Today’s AACR abstract news continues the theme of advancing EVX‑01 biomarkers and broader AI-Immunology™ applications.

Market Pulse Summary

This announcement highlights advancing EVX‑01 biomarker and immunogenicity data and extending Evaxio...

Analysis

This announcement highlights advancing EVX‑01 biomarker and immunogenicity data and extending Evaxion’s AI-Immunology™ approach into glioblastoma, with two AACR 2026 abstracts and presentations on April 22, 2026. In recent months the company also reported improved 2025 finances and extended cash into H2 2027. Investors may watch for subsequent detailed efficacy and safety results, partnership updates, and how these programs align with the broader 2026 milestone roadmap.

Key Terms

ai-immunology™, personalized cancer vaccine, biomarker, immunogenicity, +4 more

8 terms

ai-immunology™ technical

"Evaxion’s AI-Immunology™ platform in developing a personalized cancer vaccine strategy"

ai-immunology™ is the use of artificial intelligence techniques to analyze immune system data and guide the discovery, design and testing of immune-based diagnostics, vaccines and therapies. It matters to investors because it can speed up research, reduce costs and reveal promising drug targets that traditional methods might miss—like using a powerful search engine to find a few needles in a vast haystack of biological signals—potentially increasing the chance and pace of commercial returns.

personalized cancer vaccine medical

"new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01"

A personalized cancer vaccine is a medicine made to match an individual patient’s tumor and immune system, designed to train their immune cells to recognize and attack that patient’s specific cancer—like a tailor-made key developed to fit one unique lock. Investors watch this area because it promises highly targeted, potentially long-lasting treatments but also involves complex manufacturing, high development costs and regulatory uncertainty that can strongly affect company value.

biomarker medical

"One abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

immunogenicity medical

"new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01"

Immunogenicity is the ability of a substance, such as a vaccine or medication, to provoke an immune response in the body. It matters to investors because high immunogenicity can affect the effectiveness and safety of a product, potentially leading to increased costs or regulatory challenges. Understanding immunogenicity helps assess the long-term viability and market potential of pharmaceutical and biotech investments.

anti-pd-1 therapy medical

"phase 2 trial investigating EVX-01 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA"

Anti-PD-1 therapy are drugs that block the PD-1 protein on immune cells, effectively releasing the “brakes” that can prevent the body from attacking cancer cells; think of it like removing a safety lock so security guards can better recognize intruders. Investors care because these therapies can transform treatment outcomes, drive significant sales if approved for multiple cancers, and carry regulatory, patent and competitive risks that affect a company’s valuation.

endogenous retrovirus medical

"use of AI-Immunology™ to identify endogenous retrovirus (ERV)-derived neoantigens"

Endogenous retroviruses are remnants of ancient viral infections that became permanently embedded in an organism’s DNA and are inherited across generations, like fossilized viruses inside the genome. They can turn genes on or off or produce viral-like proteins, so they matter to investors because they are potential targets or safety liabilities for diagnostics, therapies and vaccines, influencing research value, regulatory review and clinical outcomes.

neoantigens medical

"endogenous retrovirus (ERV)-derived neoantigens to include in personalized vaccines"

Neoantigens are new protein fragments that appear on the surface of diseased cells, most often cancer cells, because of changes in their DNA; the immune system can recognize these as foreign. For investors, neoantigens matter because they are targets for precision therapies and vaccines that aim to teach the immune system to attack only diseased cells—think of them as unique fingerprints that enable treatments to be more specific and potentially more effective, which can drive clinical and commercial value.

glioblastoma medical

"personalized cancer vaccine strategy for glioblastoma, a deadly brain cancer"

Glioblastoma is a fast-growing and aggressive type of brain tumor that can affect a person's thinking, movement, or senses. Its seriousness and difficulty to treat can lead to significant health impacts, making it a concern for medical research and drug development. For investors, advances or setbacks in glioblastoma treatments can influence biotech companies and healthcare markets focused on cancer therapies.

AI-generated analysis. Not financial advice.

• Two abstracts accepted for presentation
• One abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01
• Another abstract on the use of Evaxion’s AI-Immunology™ platform in developing a personalized cancer vaccine strategy for glioblastoma (brain cancer)
• Evaxion will also participate in the AACR Oncology Industry Partnering event ahead of the annual meeting

COPENHAGEN, Denmark, March 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces two abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California, April 17-22, 2026.

One abstract will include new biomarker and immunogenicity data for cancer vaccine EVX-01. Designed with Evaxion’s AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).

The data stems from the phase 2 trial investigating EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced melanoma. Each patient enrolled in the trial has received a unique vaccine designed and manufactured based on their individual biology. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

The other abstract includes data on the use of AI-Immunology™ to identify endogenous retrovirus (ERV)-derived neoantigens to include in personalized vaccines to treat glioblastoma, a deadly brain cancer, for which limited therapeutic options exist.

In line with our strategy to identify potential partners and opportunities for both business partnerships and scientific collaborations, we will also participate in the AACR Oncology Industry Partnering event taking place ahead of the annual meeting.

Presentations details:
Abstract title: AI-designed personalized neoantigen vaccine, EVX-01, induces durable de novo T-cell responses in advanced melanoma patients
Poster#: 7741
Session category: Clinical research
Session title: Immune response to therapies
Location: Poster section 42
Date/Time: April 22, 2026, at 9am-12pm CST/16-19 CET 
Presenter: Mads Lausen Nielsen, PhD, Project Manager at Evaxion

Abstract title: Endogenous retrovirus-derived neoantigens enable a personalized cancer vaccine strategy for glioblastoma
Poster#: 6975
Session category: Immunology
Session title: Novel Models of Immunotherapy Response
Location: Poster section 8
Date/Time: April 22, 2026, at 9am-12pm CST/16-19 CET 
Presenter: Megan Benz, Duke University Medical Center

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

FAQ

What new EVX-01 data will Evaxion present at AACR 2026 (EVAX)?

Evaxion will present new biomarker and immunogenicity data for EVX-01 in advanced melanoma. According to Evaxion, the data come from a phase 2 trial of EVX-01 plus pembrolizumab, with each patient receiving a vaccine personalized to their individual biology.

When and where will Evaxion (EVAX) present posters at the AACR Annual Meeting?

Evaxion will present two posters on April 22, 2026, from 9:00–12:00 CST (16:00–19:00 CET) in San Diego. According to Evaxion, poster 7741 is in poster section 42 and poster 6975 is in poster section 8.

What is the glioblastoma abstract about from Evaxion (EVAX) at AACR 2026?

The glioblastoma abstract describes using AI-Immunology™ to identify ERV-derived neoantigens for personalized vaccines. According to Evaxion, this approach aims to include endogenous retrovirus-derived targets in personalized vaccine strategies for glioblastoma.

Will Evaxion (EVAX) seek partnerships at AACR 2026 and how?

Evaxion plans to participate in the AACR Oncology Industry Partnering event ahead of the annual meeting to explore partnerships. According to Evaxion, this participation is aligned with its strategy to identify business and scientific collaboration opportunities.

Who are the presenters for Evaxion (EVAX) posters at AACR 2026 and what are their roles?

Poster 7741 will be presented by Mads Lausen Nielsen, PhD, project manager at Evaxion; poster 6975 will be presented by Megan Benz from Duke University Medical Center. According to Evaxion, both presentations occur April 22, 2026, at 9:00–12:00 CST.